Hikma Pharmaceuticals HIK

LON: HIK | ISIN: GB00B0LCW083 30/04/2025

1.985,00 GBX (+1,22%)

(+1,22%) 30/04/2025

Toon enkel gratis nieuws

17 april 2025 · Hikma acquires Novugen's FDA-approved ANDA for trametinib · Persbericht

20 augustus 2024 · Hikma Pharmaceuticals participates in naloxone training event with U.S. Congressman Buddy Carter ahead of National Fentanyl Awareness and Prevention Day · Persbericht

15 augustus 2024 · KLOXXADO® 8mg Naloxone Nasal Spray Shelf-Life Extended from 24 months to 36 months · Persbericht

21 februari 2024 · Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility · Persbericht

5 februari 2024 · Hikma announces US launch of COMBOGESIC® IV · Persbericht

3 oktober 2023 · Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US · Persbericht

10 augustus 2023 · Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa · Persbericht

26 juli 2023 · Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases · Persbericht

15 juni 2023 · Hikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USP · Persbericht

9 maart 2023 · Hikma expands impact in Canada with launches of new sterile injectable medicines · Persbericht

30 augustus 2022 · Hikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the US · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe